In This Article:
BOUCHERVILLE, QC, Sept. 26, 2024 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) ("LSL Pharma" or the "Corporation"), an integrated Canadian-based pharmaceutical Corporation, today announced a change of auditor from KPMG LLP (the "Predecessor Auditor") to Audacie Inc. (the "Successor Auditor").
The Predecessor Auditor has resigned as auditor of the Corporation effective September 25, 2024 at the request of the Corporation to facilitate the appointment of Audacie as successor auditor of the Corporation. The Board of Directors of the Corporation, on the recommendation of the Corporation's Audit Committee, approved the appointment of the Successor Auditor to replace the Predecessor Auditor, effective September 25, 2024.
There were no modified opinions in the Predecessor Auditor's audit reports relating to the fiscal years ended December 31, 2023 and 2022 or any subsequent period until its resignation date and there is no "reportable event" as such term is defined in Part 4.11 of National Instrument 51-102- Continuous Disclosure Obligations ("NI 51-102").
The Corporation has filed the change of auditor reporting package on SEDAR+ in accordance with NI 51-102.
GRANT OF OPTIONS
The Corporation also announces the grant of an aggregate of 465,270 stock options (the "Options") to certain officers and directors in accordance with the Corporation's long-term incentive compensation plan. The Options will be exercisable at a price of $0.45 per Class A common share, will vest over three years and have a ten-year term.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements as defined under applicable Canadian securities legislation. Forward-looking statements can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "continue" or similar expressions. Forward-looking statements are based on a number of assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Corporation's ability to control or predict, that could cause actual results or performance to differ materially from those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, those identified in the Corporation's filings with Canadian securities regulatory authorities, such as legislative or regulatory developments, increased competition, technological change and general economic conditions. All forward-looking statements made herein should be read in conjunction with such documents.